Share chart AbbVie
Extended chart
Simple chart
About AbbVie
19 октября 2011 года Abbott Laboratories объявила о своем плане разделения на две публично торгуемые компании. » Новые " лаборатории Abbott будут специализироваться на разнообразных продуктах, включая медицинские приборы, диагностическое оборудование и продукты питания, в то время как AbbVie будет работать как фармацевтический производитель, основанный на исследованияхIPO date | 2013-01-02 |
---|---|
ISIN | US00287Y1091 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 3.05 |
Дивиденд ао | 1.64 |
Сайт | http://www.abbvie.com |
Цена ао | 190.07 |
Change price per day: | +2.96% (184.6) |
---|---|
Change price per week: | +1.56% (187.15) |
Change price per month: | +8.58% (175.05) |
Change price per 3 month: | -0.9175% (191.83) |
Change price per half year: | +11.58% (170.35) |
Change price per year: | +17.85% (161.28) |
Change price per 3 year: | +30.91% (145.19) |
Change price per 5 year: | +82.27% (104.28) |
Change price per 10 year: | +200.41% (63.27) |
Change price per year to date: | +5.59% (180) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
0.86% | 1.639 | I кв. 2025 | 11.04.2025 | 15.04.2025 | 30.04.2025 |
0.85% | 1.639 | IV кв. 2024 | 13.01.2025 | 15.01.2025 | 30.01.2025 |
0.88% | 1.55 | II кв. 2024 | 12.07.2024 | 15.07.2024 | 30.07.2024 |
0.96% | 1.55 | I кв. 2024 | 10.04.2024 | 12.04.2024 | 29.04.2024 |
1.01% | 1.55 | IV кв. 2023 | 10.01.2024 | 12.01.2024 | 29.01.2024 |
0.97% | 1.48 | III кв. 2023 | 10.10.2023 | 12.10.2023 | 27.10.2023 |
1.11% | 1.48 | II кв. 2023 | 11.07.2023 | 13.07.2023 | 28.07.2023 |
0.95% | 1.48 | I кв. 2023 | 11.04.2023 | 13.04.2023 | 28.04.2023 |
0.91% | 1.48 | IV кв. 2022 | 10.01.2023 | 12.01.2023 | 27.01.2023 |
0.99% | 1.41 | III кв. 2022 | 11.10.2022 | 13.10.2022 | 28.10.2022 |
Institutions | Volume | Share, % |
---|---|---|
Vanguard Group Inc | 160398331 | 9.06 |
Blackrock Inc. | 143182709 | 8.09 |
State Street Corporation | 78200866 | 4.42 |
JP Morgan Chase & Company | 51818311 | 2.93 |
Capital International Investors | 44988183 | 2.54 |
Geode Capital Management, LLC | 37017486 | 2.09 |
Morgan Stanley | 34052535 | 1.92 |
Capital Research Global Investors | 30302654 | 1.71 |
Charles Schwab Investment Management, Inc. | 24451975 | 1.38 |
Bank Of New York Mellon Corporation | 22104491 | 1.25 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Richard A. Gonzalez | Executive Chairman | 7.19M | 1954 (71 year) |
Mr. Robert A. Michael | CEO & Director | 4.62M | 1970 (55 years) |
Ms. Elizabeth Shea | Senior Vice President of Investor Relations | N/A | |
Mr. Timothy J. Richmond | Executive VP & Chief Human Resources Officer | 1.12M | 1966 (59 years) |
Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 4.32M | 1969 (56 years) |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO | 3.51M | 1963 (62 years) |
Mr. Scott T. Reents | Executive VP & CFO | 3.13M | 1968 (57 years) |
Mr. Sanjay Narayan | Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal | N/A | |
Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | N/A | 1975 (50 years) |
Dr. Roopal Thakkar M.D. | Executive VP of Research and Development & Chief Scientific Officer | 1972 (53 years) |
Address: United States, North Chicago, 1 North Waukegan Road - open in Google maps, open in Yandex maps
Website: http://www.abbvie.com
Website: http://www.abbvie.com